Search Results

A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients by Scagliotti, Giorgio V. (Author) , Moro-Sibilot, Denis (Author) , Kollmeier, Jens (Author) , Favaretto, Adolfo (Author) , Cho, Eun Kyung (Author) , Grosch, Heidrun (Author) , Kimmich, Martin (Author) , Girard, Nicolas (Author) , Tsai, Chun-Ming (Author) , Hsia, Te-Chun (Author) , Brighenti, Matteo (Author) , Schumann, Christian (Author) , Wang, Xuejing Aimee (Author) , Wijayawardana, Sameera R. (Author) , Gruver, Aaron M. (Author) , Wallin, Johan (Author) , Mansouri, Kambiz (Author) , Wacheck, Volker (Author) , Chang, Gee-Chen (Author) ,

• lizenzpflichtig
• lizenzpflichtig